HUP0001931A2 - Kémiai vegyületek - Google Patents

Kémiai vegyületek

Info

Publication number
HUP0001931A2
HUP0001931A2 HU0001931A HUP0001931A HUP0001931A2 HU P0001931 A2 HUP0001931 A2 HU P0001931A2 HU 0001931 A HU0001931 A HU 0001931A HU P0001931 A HUP0001931 A HU P0001931A HU P0001931 A2 HUP0001931 A2 HU P0001931A2
Authority
HU
Hungary
Prior art keywords
cell
targeting part
human
gene construct
chemical compounds
Prior art date
Application number
HU0001931A
Other languages
English (en)
Inventor
David Charles Blakey
Stephen Charles Emery
Original Assignee
Zeneca Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Limited filed Critical Zeneca Limited
Publication of HUP0001931A2 publication Critical patent/HUP0001931A2/hu
Publication of HUP0001931A3 publication Critical patent/HUP0001931A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y10S977/804—Containing nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

A találmány őlyan génkőnstrűkciót biztősít, amely egy sejt becélzó,részt és egy heterőlóg előgyógyszer aktiváló enzimet kódőlgyógyszerként való felhasználásra emberi vagy emlős állatgazdaszervezetben, ahől a nevezett génkőnstrűkció, kőnjűgátűmkéntképes expresszálni a sejt becélzó részt és az enzimet az emberi vagyemlős állat gazdaszervezet célsejtjén belül és ahől a kőnjűgátűm úgyvan irányítva, hőgy ezűtán elhagyja a sejtet a szelektívelhelyezkedéshez a sejt becélzó rész által felismert sejtfelületiantigénnél. ŕ
HU0001931A 1997-05-10 1998-05-05 Chemical compounds HUP0001931A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9709421.3A GB9709421D0 (en) 1997-05-10 1997-05-10 Chemical compounds
PCT/GB1998/001294 WO1998051787A2 (en) 1997-05-10 1998-05-05 Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety

Publications (2)

Publication Number Publication Date
HUP0001931A2 true HUP0001931A2 (hu) 2000-09-28
HUP0001931A3 HUP0001931A3 (en) 2003-10-28

Family

ID=10812048

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0001931A HUP0001931A3 (en) 1997-05-10 1998-05-05 Chemical compounds

Country Status (23)

Country Link
US (1) US6339070B1 (hu)
EP (1) EP0979292B1 (hu)
JP (1) JP2001526539A (hu)
KR (1) KR100508136B1 (hu)
CN (1) CN1268743C (hu)
AT (1) ATE412755T1 (hu)
AU (1) AU734915B2 (hu)
BR (1) BR9808769A (hu)
CA (1) CA2286875A1 (hu)
DE (1) DE69840165D1 (hu)
ES (1) ES2314990T3 (hu)
GB (2) GB9709421D0 (hu)
HU (1) HUP0001931A3 (hu)
IL (1) IL132348A0 (hu)
MY (1) MY140975A (hu)
NO (1) NO995475L (hu)
NZ (1) NZ500014A (hu)
PL (1) PL337007A1 (hu)
RU (1) RU2218404C2 (hu)
SK (1) SK153599A3 (hu)
TR (1) TR199902731T2 (hu)
WO (1) WO1998051787A2 (hu)
ZA (1) ZA983931B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9910077D0 (en) 1999-05-01 1999-06-30 Univ Manchester Chemical compounds
DE19946142A1 (de) * 1999-09-27 2001-03-29 Bundesrepublik Deutschland Let Gentransfer in humane Lymphocyten mittels retroviraler scFv-Zelltargeting Vektoren
GB0001653D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Uk Ltd Chemical compound
GB0102239D0 (en) 2001-01-29 2001-03-14 Cancer Res Ventures Ltd Methods of chemical synthisis
WO2002094318A1 (en) * 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
US7244592B2 (en) * 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
WO2003104425A2 (en) * 2002-06-07 2003-12-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Novel stable anti-cd22 antibodies
US20050107320A1 (en) * 2003-01-30 2005-05-19 Matthew During Methods and compositions for use in interventional pharmacogenomics
PT2382990E (pt) 2003-04-30 2014-12-29 Univ Zuerich Método para tratamento do cancro usando uma imunotoxina
US20110160440A1 (en) * 2003-12-12 2011-06-30 Genencor International, Inc. Cab Molecules
TWI351284B (en) 2004-04-09 2011-11-01 Chugai Pharmaceutical Co Ltd Novel water-soluble prodrugs
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
JP5463036B2 (ja) * 2005-12-21 2014-04-09 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 可溶性ｃｅａに対する抵抗性を有する医薬抗体組成物
US8263744B2 (en) * 2007-04-19 2012-09-11 Viventia Biotechnologies Inc. Binding proteins that bind to EpCAM linked to an effector molecule
CA2700815A1 (en) * 2007-09-27 2009-04-02 Viventia Biotech Inc. Optimized nucleic acid sequences for the expression of vb4-845
US8771679B2 (en) 2008-08-13 2014-07-08 The John Hopkins University Prodrug activation in cancer cells using molecular switches
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
SG11201401518TA (en) * 2011-10-28 2014-05-29 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
PT2880160T (pt) 2012-08-03 2018-12-17 Cedars Sinai Medical Center Isolamento de mutantes que aumentam o tráfego de proteínas para administração de fármacos
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
AU2014331494A1 (en) 2013-10-02 2016-04-07 Viventia Bio Inc. Anti-EpCAM antibodies and methods of use
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
KR102639037B1 (ko) 2014-10-29 2024-02-20 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 인터페론 α2b 변이체
CN107580501A (zh) 2015-03-12 2018-01-12 维文蒂亚生物公司 用于靶向epcam阳性膀胱癌的给药策略
AU2016228755B2 (en) 2015-03-12 2020-09-10 Viventia Bio Inc. Methods of treatment for EPCAM positive bladder cancer
JP2023520764A (ja) 2020-03-24 2023-05-19 ジェネレーション バイオ カンパニー 第ｉｘ因子治療薬を発現するための非ウイルス性ｄｎａベクター及びその使用
IL296662A (en) 2020-03-24 2022-11-01 Generation Bio Co Non-viral DNA vectors and their use for expression of Gauche cure
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0845537A1 (en) 1989-08-18 1998-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
DE4110409C2 (de) 1991-03-29 1999-05-27 Boehringer Ingelheim Int Neue Protein-Polykation-Konjugate
WO1993019163A1 (en) 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
GB9314960D0 (en) * 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds
EP0670905B1 (en) 1992-09-22 2003-07-23 Biofocus Discovery Limited Recombinant viruses displaying a nonviral polypeptide on their external surface
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
GB9323008D0 (en) 1993-11-05 1994-01-05 Connors Thomas Improvements relating to cancer therapy
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
GB9423367D0 (en) 1994-11-18 1995-01-11 Wellcome Found Enzyme prodrug therapy
US5985281A (en) * 1994-12-23 1999-11-16 Zeneca Limited Chemical compounds
GB2317387B (en) * 1995-08-16 1999-08-18 Zeneca Ltd Chemical compounds
GB9523703D0 (en) 1995-11-20 1996-01-24 Wellcome Found Enzyme prodrug thearapy
GB9601640D0 (en) 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
ATE350478T1 (de) * 1996-05-04 2007-01-15 Astrazeneca Ab Monoklonaler antikoerper gegen cea, konjugate die dieses antikoerper enthalten und deren therapeutische verwendung in einem adept-system
EP1717248A1 (en) 1997-06-04 2006-11-02 Oxford Biomedica (UK) Limited Tumor targeted vector

Also Published As

Publication number Publication date
BR9808769A (pt) 2000-08-01
CA2286875A1 (en) 1998-11-19
ZA983931B (en) 1998-11-10
NO995475D0 (no) 1999-11-09
AU734915B2 (en) 2001-06-28
DE69840165D1 (de) 2008-12-11
RU2218404C2 (ru) 2003-12-10
GB9922815D0 (en) 1999-11-24
NO995475L (no) 2000-01-07
KR20010012441A (ko) 2001-02-15
JP2001526539A (ja) 2001-12-18
AU7225498A (en) 1998-12-08
MY140975A (en) 2010-02-12
WO1998051787A3 (en) 1999-04-01
HUP0001931A3 (en) 2003-10-28
CN1268743C (zh) 2006-08-09
TR199902731T2 (xx) 2000-06-21
EP0979292B1 (en) 2008-10-29
GB2338484A (en) 1999-12-22
US6339070B1 (en) 2002-01-15
GB9709421D0 (en) 1997-07-02
CN1255163A (zh) 2000-05-31
ES2314990T3 (es) 2009-03-16
GB2338484B (en) 2001-11-07
NZ500014A (en) 2001-08-31
ATE412755T1 (de) 2008-11-15
IL132348A0 (en) 2001-03-19
KR100508136B1 (ko) 2005-08-10
SK153599A3 (en) 2000-06-12
PL337007A1 (en) 2000-07-31
EP0979292A2 (en) 2000-02-16
WO1998051787A2 (en) 1998-11-19

Similar Documents

Publication Publication Date Title
HUP0001931A2 (hu) Kémiai vegyületek
AU2989300A (en) Controlling protein levels in eucaryotic organisms
NO20050497L (no) Anvendelse av CETP inhibitorer og eventuelt HMG COA reduserbare inhibitorer og/eller antihypertensiva
NO20042694L (no) 17 alfa-alkyl-17 beta-oksy-ostratriener og mellomprodukter for fremstilling av disse, anvendelse av 17 alfa-alkyl-17 beta-oksy-ostratrienene til fremstilling av legemidler samt farmasoytiske preparater
BR9805544C1 (pt) Uso de um composto.
TR199901667T2 (xx) 3-Heterosiklil-ikame edilmi� benzoil t�revleri
WO2001087227A3 (en) Drug containing polymeric micelles
NO20055209L (no) Peptabody for cancerbehandling
HUP9802961A2 (hu) Kötési partner ciklinfüggő kinázok inhibitoraihoz és ezek alkalmazása inhibitorok kereséséhez, valamint egy betegség diagnózisához vagy terápiájához
TR200003759T2 (tr) Epotilonların biyosentezi için genler
BR9815335A (pt) Uso de antagonistas de receptor de endotelina.
WO2003070889A3 (en) Prostate specific genes and the use thereof in design or therapeutics
PT946730E (pt) Mutantes de toxina estreptococica c e metodos de utilizacao
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
DE59611307D1 (de) Nucleinsäure-moleküle codierend proteine, die die adhäsion von neisseria-zellen an humane zellen vermitteln
BR0014192A (pt) Conjugados de corantes e anticorpos contra estruturas-alvo da angiogênese, para representação intra-operativa da margem de tumores
WO2007031574A3 (en) Therapeutic use of outer shigella protein f (os pf)
BR0009221A (pt) Vetores virais de inseto e usos dos mesmos
ATE346924T1 (de) P-glycoproteine und ihre verwendungen
PT1267940E (pt) Compostos para direccionamento
IT1306190B1 (it) Mutanti di proteine e plasmidi idonei per la loro sintesi.
NO995068L (no) Anvendelser av steinavleiring
PT980379E (pt) Oligonucleotidos quimericos e sua utilizacao
BR0007814A (pt) Uso de anticorpos para a vacinação contra câncer
ITRM20020511A1 (it) Uso dell'insulator sns di riccio di mare per la terapia genica di malattie delle cellule eritroidi.

Legal Events

Date Code Title Description
FC4A Lapse of provisional application due to refusal